1. Home
  2. CPIX vs CUE Comparison

CPIX vs CUE Comparison

Compare CPIX & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CPIX
  • CUE
  • Stock Information
  • Founded
  • CPIX 1999
  • CUE 2014
  • Country
  • CPIX United States
  • CUE United States
  • Employees
  • CPIX N/A
  • CUE N/A
  • Industry
  • CPIX Biotechnology: Pharmaceutical Preparations
  • CUE Biotechnology: Pharmaceutical Preparations
  • Sector
  • CPIX Health Care
  • CUE Health Care
  • Exchange
  • CPIX Nasdaq
  • CUE Nasdaq
  • Market Cap
  • CPIX 68.7M
  • CUE 60.6M
  • IPO Year
  • CPIX 2009
  • CUE 2018
  • Fundamental
  • Price
  • CPIX $4.76
  • CUE $0.76
  • Analyst Decision
  • CPIX
  • CUE Strong Buy
  • Analyst Count
  • CPIX 0
  • CUE 3
  • Target Price
  • CPIX N/A
  • CUE $3.00
  • AVG Volume (30 Days)
  • CPIX 43.3K
  • CUE 206.6K
  • Earning Date
  • CPIX 05-06-2025
  • CUE 05-08-2025
  • Dividend Yield
  • CPIX N/A
  • CUE N/A
  • EPS Growth
  • CPIX N/A
  • CUE N/A
  • EPS
  • CPIX N/A
  • CUE N/A
  • Revenue
  • CPIX $37,867,945.00
  • CUE $9,287,000.00
  • Revenue This Year
  • CPIX N/A
  • CUE N/A
  • Revenue Next Year
  • CPIX N/A
  • CUE $4.77
  • P/E Ratio
  • CPIX N/A
  • CUE N/A
  • Revenue Growth
  • CPIX N/A
  • CUE 69.16
  • 52 Week Low
  • CPIX $1.04
  • CUE $0.45
  • 52 Week High
  • CPIX $7.25
  • CUE $2.26
  • Technical
  • Relative Strength Index (RSI)
  • CPIX 56.04
  • CUE 39.49
  • Support Level
  • CPIX $3.98
  • CUE $0.72
  • Resistance Level
  • CPIX $4.41
  • CUE $0.89
  • Average True Range (ATR)
  • CPIX 0.30
  • CUE 0.10
  • MACD
  • CPIX 0.06
  • CUE 0.02
  • Stochastic Oscillator
  • CPIX 98.00
  • CUE 48.59

About CPIX Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

Share on Social Networks: